MARKET

SYBX

SYBX

Synlogic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.990
+0.190
+5.00%
Closed 16:00 03/02 EST
OPEN
3.840
PREV CLOSE
3.800
HIGH
4.140
LOW
3.810
VOLUME
265.84K
TURNOVER
--
52 WEEK HIGH
5.11
52 WEEK LOW
1.350
MARKET CAP
156.94M
P/E (TTM)
-2.4264
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Synlogic Granted US Patent Titled 'Bacteria engineered to treat a disease or disorder'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10933102.PN.&OS=PN/10933102&RS=PN/10933102
Benzinga · 19h ago
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
CAMBRIDGE, Mass., Feb. 15, 2021 /PRNewswire via COMTEX/ -- CAMBRIDGE, Mass., Feb. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage...
PR Newswire - PRF · 02/15 12:00
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11)
Benzinga · 02/11 12:26
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10)
Benzinga · 02/10 12:34
Synlogic Names Lisa Kelly-Croswell to Bd of Directors
Synlogic Names Lisa Kelly-Croswell to Bd of Directors
Dow Jones · 02/10 12:07
Synlogic Appoints Lisa Kelly-Croswell to its Board of Directors
PR Newswire · 02/10 12:00
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 9)
Benzinga · 02/09 13:10
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 4)
Benzinga · 02/05 12:44
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYBX. Analyze the recent business situations of Synlogic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYBX stock price target is 9.17 with a high estimate of 13.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 99
Institutional Holdings: 25.38M
% Owned: 64.53%
Shares Outstanding: 39.33M
TypeInstitutionsShares
Increased
15
601.72K
New
18
3.19M
Decreased
10
365.43K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Independent Director
Peter Barrett
President/Chief Executive Officer/Director
Aoife Brennan
Chief Financial Officer
Gregg Beloff
Other
David Hava
Other
Richard Riese
Other
Michael Slater
Director
Michael Heffernan
Director
Lisa Kelly-Croswell
Independent Director
Michael Burgess
Independent Director
Patricia Hurter
Independent Director
Chau Khuong
Independent Director
Nick Leschly
Independent Director
Edward Mathers
Independent Director
Richard Shea
  • Dividends
  • Splits
  • Insider Activity
No Data
About SYBX
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Webull offers kinds of Synlogic Inc stock information, including NASDAQ:SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.